Core Viewpoint - ADMA Biologics is experiencing a mix of positive and negative market sentiments, influenced by recent analyst ratings, stock performance, and insider trading activities [1][5][7]. Analyst Ratings - Weiss Ratings maintained a "hold (c)" rating, while Zacks Research upgraded the stock from "hold" to "strong-buy" [1] - Wall Street Zen also upgraded the stock from "hold" to "buy" [1] - Cantor Fitzgerald reiterated a "neutral" rating, resulting in a consensus rating of "Buy" with a price target of $32.00 [1] Stock Performance - ADMA Biologics stock increased by 11.6%, with a market capitalization of $2.20 billion and a P/E ratio of 15.42 [2] - The stock's fifty-day moving average is $15.60, and the two-hundred-day moving average is $16.42 [2] Quarterly Earnings - The company reported earnings per share (EPS) of $0.20, meeting the consensus estimate [3] - Revenue for the quarter was $139.16 million, an 18.4% increase year-over-year, but slightly below analysts' expectations of $139.80 million [3] Insider Trading - Director Steve Elms purchased 7,000 shares at an average cost of $15.67, increasing his position by 0.34% [6] - COO Kaitlin M. Kestenberg-Messina sold 10,096 shares at an average price of $15.63, decreasing her position by 2.12% [6] Institutional Activity - Institutional ownership stands at 75.68%, with several hedge funds increasing their positions significantly [7] - Rothschild Investment LLC raised its stake by 373.8%, now owning 1,895 shares valued at $28,000 [7] Company Overview - ADMA Biologics is a biopharmaceutical company focused on developing and commercializing specialty plasma-derived biologics for treating primary immunodeficiency and infectious diseases [8] - The company operates an integrated model that includes plasma collection, fractionation, formulation, and fill-finish operations [8]

Core Viewpoint - The company ADMA Biologics refutes allegations made by short seller Culper Research regarding its immune globulin product ASCENIV, emphasizing that demand and utilization have steadily increased over the past two years, reaching record levels [1][2]. Group 1: Demand and Utilization - Demand for ASCENIV has shown significant growth, with data from distribution partners indicating an increase in end-user demand over the past two-plus years [5]. - As of January 5, 2026, and March 22, 2026, average inventory days on hand for ASCENIV were reported at 84 and 48 days, respectively, exceeding the distributors' minimum requirements [7]. - The company maintains that its distributors stock above the minimum levels to ensure continuity of care for immune-compromised patients who require therapy every 21-28 days [6]. Group 2: Inventory Management - Inventory levels for ASCENIV and BIVIGAM are consistent with industry standards, with average days of inventory on hand reported at 128 and 90 days for ASCENIV as of January 5, 2026, and March 22, 2026, respectively [10]. - The company asserts that these inventory levels are appropriately sized to ensure proper handling and mitigate potential supply chain disruptions [10]. Group 3: Competitive Positioning - ASCENIV is positioned as a late-line therapy for immune-compromised individuals who do not respond to standard immunoglobulin treatments, allowing it to command premium pricing [15]. - The short report's claims regarding competitive pressure from new immune globulin product launches are described as misguided by the company [15][13]. Group 4: Financial Integrity - ADMA has received unqualified opinions in its audits for FY 2024 and FY 2025, confirming the effectiveness of its internal controls over financial reporting [14]. - The company has filed its Annual Reports on Form 10-K for the years ended December 31, 2024, and 2025, with no undisclosed related party transactions reported [15].

Core Viewpoint - ADMA Biologics, Inc. has responded to a negative report by Culper Research, which holds a short position in the company, asserting that the report is based on speculative and unreliable sources, while ADMA emphasizes its commitment to accurate financial reporting and compliance with regulations [1]. Group 1: Company Overview - ADMA Biologics is a U.S.-based biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [2]. - The company currently offers three FDA-approved plasma-derived biologics: ASCENIV™ for primary humoral immunodeficiency, BIVIGAM for primary immunodeficiency, and NABI-HB for hepatitis B immunity [2]. - ADMA is also developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia, and operates an FDA-licensed plasma fractionation facility in Boca Raton, Florida [2]. Group 2: Regulatory Compliance and Response - ADMA's Board of Directors is committed to fair and accurate reporting of its financial results and adheres to U.S. Securities and Exchange Commission regulations and U.S. GAAP standards [1]. - The company is taking steps to review the assertions made in the Short Report, which it claims contains numerous misleading and inaccurate statements [1].

Core Insights - B Group Inc. increased its stake in ADMA Biologics by 4.1% in Q3, owning 2,412,542 shares, which constitutes 26.9% of its holdings, valued at approximately $35.37 million [2] - Several institutional investors have also increased their positions in ADMA Biologics, with Marathon Capital Management raising its stake by 64.5% and Comerica Bank by 821.9% during the same period [3] - ADMA Biologics reported a revenue of $139.16 million for the last quarter, reflecting an 18.4% year-over-year increase, with an EPS of $0.20, matching analysts' expectations [5] Institutional Holdings - Institutional investors own 75.68% of ADMA Biologics' stock, indicating strong institutional interest [3] - Notable increases in holdings include Marathon Capital Management (64.5% increase) and Comerica Bank (821.9% increase) [3] Price Performance - ADMA Biologics shares opened at $15.15, with a 12-month low of $13.76 and a high of $25.67 [4] - The company has a market capitalization of $3.61 billion and a price-to-earnings ratio of 25.25 [4] Analyst Ratings - Zacks Research upgraded ADMA Biologics from "hold" to "strong-buy," while Wall Street Zen upgraded it from "hold" to "buy" [6] - The consensus rating for ADMA Biologics is "Buy," with a target price of $32.00 [6] Insider Transactions - Director Steve Elms purchased 7,000 shares at an average cost of $15.67, increasing his position by 0.34% [7] - COO Kaitlin M. Kestenberg-Messina sold 10,096 shares at an average price of $15.63, decreasing her ownership by 2.12% [7] Company Overview - ADMA Biologics is a biopharmaceutical company focused on developing and commercializing specialty plasma-derived biologics for treating primary immunodeficiency and infectious diseases [8] - The company's product portfolio includes BIVIGAM, a human immunoglobulin intravenous therapy approved in the U.S. [9]

Core Insights - ADMA Biologics reported a total revenue of $510 million for FY 2025, reflecting a 20% year-over-year growth, primarily driven by increased sales of ASCENIV [1][9] - ASCENIV revenue reached $363 million, marking a significant 51% year-over-year increase, indicating strong demand and adoption in the market [1][42] - The company achieved an adjusted net income of $161 million, representing a 35% year-over-year growth, and an adjusted EBITDA of $231 million, which is a 40% increase from the previous year [1][14] Financial Performance - Total revenue for FY 2025 was $510.2 million, up from $426.5 million in FY 2024, an increase of $83.7 million or 20% [9] - Gross profit for FY 2025 was $292.8 million, resulting in a gross margin of 57.4%, compared to 51.5% in FY 2024 [10] - Adjusted net income for FY 2025 was $160.8 million, compared to $119.2 million in FY 2024, representing a growth of 35% [13] - Adjusted EBITDA for FY 2025 was $231 million, up from $164.6 million in FY 2024, reflecting a 40% increase [14] Strategic Developments - The appointment of a new CFO is expected to enhance financial strategy, working capital execution, and capital allocation discipline [1][5] - The company is advancing its SG-001 pipeline program with an anticipated FDA pre-IND meeting in 2026, which may lead to a registrational trial [1][17] - Ongoing share repurchases and a focus on capital structure are aimed at increasing stockholder value [1] Future Guidance - For FY 2026, total revenue is expected to exceed $635 million, with adjusted net income anticipated to exceed $255 million and adjusted EBITDA expected to exceed $360 million [6] - FY 2027 total revenue is projected to exceed $775 million, with adjusted net income expected to exceed $315 million and adjusted EBITDA anticipated to exceed $455 million [6] - The company is targeting over $1.1 billion in total annual revenue by FY 2029, translating to at least $700 million in adjusted EBITDA [6]

Core Viewpoint - ADMA Biologics, Inc. will report its fourth quarter and full year 2025 financial results on February 25, 2026, followed by a conference call to discuss these results and company updates [1]. Group 1: Company Overview - ADMA Biologics is a U.S.-based biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3]. - The company currently offers three FDA-approved plasma-derived biologics: ASCENIV™, BIVIGAM, and NABI-HB, aimed at treating immune deficiencies and preventing certain infectious diseases [3]. - ADMA is also developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia [3]. - The company operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and has a subsidiary, ADMA BioCenters, which collects source plasma for its products [3]. - ADMA holds numerous U.S. and foreign patents related to its products and candidates [3].

Core Insights - ADMA Biologics has provided strong revenue guidance for 2025, 2026, and 2027, with expectations of over $510 million in revenue for 2025, $635 million for 2026, and $775 million for 2027, alongside significant EBITDA projections [2][6][19] Financial Performance - For 2025, ADMA anticipates revenue exceeding $510 million, with EBITDA around $235 million and net income greater than $158 million [2] - The company expects fourth-quarter 2025 revenue to surpass $139 million, with EBITDA between $77 million and $78 million, and net income around $50 million [2][6] - Long-term projections include a target of $1.1 billion in revenue and approximately $700 million in EBITDA by 2029 [1][6] Product and Market Focus - ADMA's primary product, Asceniv, is a respiratory-focused immune globulin, with the company holding three FDA-approved commercial products [3][7] - The IVIG market is projected to grow from over $13 billion in 2024 to more than $30 billion by 2033, with ADMA capturing about 3% of the U.S. immunoglobulin market [8] - The total addressable market for Asceniv is estimated at 25,000 patients, with ADMA currently serving over 1,000 patients [8] Manufacturing and Supply Chain Developments - ADMA is divesting three plasma centers for approximately $12 million, which will help reduce operating costs by $13 million to $15 million [4][14] - The company has secured long-term supply contracts and expanded third-party plasma collection to over 280 centers, ensuring a steady supply of raw materials for Asceniv [4][15] - An FDA-approved yield enhancement strategy allows ADMA to produce 20% more finished goods per plasma unit, which is expected to improve margins starting in 2026 [5][11] Pipeline and Future Opportunities - ADMA plans to pursue a pediatric label expansion for Asceniv and is developing the SG01 program, which could represent a revenue opportunity of $300 million to $500 million if successful [19] - The SG01 program is not included in the 2029 revenue guidance but has an intellectual property runway through 2037 [4][19]

ADMA Biologics Realizing the Potential of Specialty Biologics with Groundbreaking Immunotechnology January 2026 NASDAQ: ADMA Forward-Looking Statements This presentation contains "forward-looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. and its subsidiaries (collectively, "we," "our" or the "Company"), including, without limitation, statements that may predict, forecast, indicate, or imply future results, performan ...

Core Viewpoint - ADMA Biologics, Inc. will participate in the J.P. Morgan Healthcare Conference on January 12, 2026, highlighting its focus on specialty biologics for immunodeficient patients [1]. Company Overview - ADMA Biologics is a U.S.-based biopharmaceutical company that manufactures, markets, and develops specialty biologics aimed at treating immunodeficient patients and those at risk for infectious diseases [3]. - The company currently offers three FDA-approved plasma-derived biologics: ASCENIV™ for primary humoral immunodeficiency, BIVIGAM for primary immunodeficiency, and NABI-HB for enhanced immunity against hepatitis B [3]. - ADMA is also developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia [3]. - The company operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and has a subsidiary, ADMA BioCenters, which collects source plasma for its products [3]. - ADMA holds numerous U.S. and foreign patents related to its products and candidates [3].

Company Overview - ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally [4]. Product Portfolio - The company markets BIVIGAM, an intravenous immune globulin product for treating primary humoral immunodeficiency, and Nabi-HB, a human polyclonal antibody product for acute exposure to blood containing Hepatitis B surface antigen [2][4]. Financial Performance - In the third quarter of 2025, ADMA Biologics updated its revenue guidance for 2025, now expecting total revenue of $510 million, an increase from the previous guidance of over $500 million [3]. - The adjusted net income for 2025 was also revised to $158 million, reflecting a higher effective tax rate [3].